Results 61 to 70 of about 32,127 (239)
Therapeutic targeting of chromatin alterations in leukemia and solid tumors
International Journal of Cancer, EarlyView.Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner +7 more
wiley +1 more source
Hydroxyurea-Induced Pneumopathy in a Patient With Myeloproliferative Syndrome
Clinical Medicine Insights: Case Reports, 2018 Hydroxyurea (HU) is a drug frequently used in the treatment of chronic myeloproliferative neoplasms. The most common side effects of this drug are pancytopenia, digestive and skin disorders.
Oriol Plans Galván +5 more
doaj +1 more source
Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation
Hematology, Transfusion and Cell Therapy, 2018 Background: Cytokines are key immune mediators in physiological and disease processes, whose increased levels have been associated with the physiopathology of hematopoietic malignancies, such as myeloproliferative neoplasms.
Maira da Costa Cacemiro +11 more
doaj +1 more source
The Hematopoietic Niche in Myeloproliferative Neoplasms [PDF]
Mediators of Inflammation, 2015 Specialized microanatomical areas of the bone marrow provide the signals that are mandatory for the maintenance and regulation of hematopoietic stem cells (HSCs) and progenitor cells. A complex microenvironment adjacent to the marrow vasculature (vascular niche) and close to the endosteum (endosteal niche) harbors multiple cell types including ...
Schmitt-Gräff, Annette +2 more
openaire +4 more sources
International Journal of Cancer, EarlyView.What's New? Childhood cancer ranks among the leading causes of disease‐related deaths in children in high‐income countries. Established risk factors, however, account for only a small proportion of incident childhood cancers. In this report, the authors present the first long‐term assessment of temporal trends in childhood cancer incidence rates in ...
Friederike Erdmann +8 more
wiley +1 more source
Haematologica, 2017 High mobility group AT-hook 2 (HMGA2) is an architectural transcription factor that is negatively regulated by let-7 microRNA through binding to it’s 3′-untranslated region. Transgenic mice expressing Hmga2 with a truncation of its 3′-untranslated region
Chih-Cheng Chen +11 more
doaj +1 more source
Myeloproliferative Neoplasms: An Overview [PDF]
American Society for Clinical Laboratory Science, 2011 1. Kathleen Finnegan, MS, MT(ASCP)SHCM[⇑][1] 1. Stony Brook University Health Science Center, School of Health Technology and Management, Stony Brook, NY 1. Address for Correspondence: Kathleen Finnegan, MS, MT(ASCP)SHCM, Chair, Department of Clinical Laboratory Sciences, Stony Brook University Health Science Center, School of Health ...
openaire +3 more sources
Med Research, EarlyView.ABSTRACT With the global aging trend intensifying, cancer presents a significant health challenge for the elderly. This study aims to assess the prevalence, mortality, and disability‐adjusted life years (DALY) burden of cancer among individuals aged 60–94 worldwide from 1990 to 2021.
Xiaohan Zhu +4 more
wiley +1 more source
Arterial and Venous Thrombosis in Patients with Myeloproliferative Neoplasms
Jurnal Penyakit Dalam Indonesia, 2019 Introduction. Myeloproliferative neoplasm (MPN) is a hematologic disorder that consists of polycythemia vera (PV), essential thrombocythemia (ET and primary myelofibrosis (PMF) and complication of thrombosis is frequently found in patients with MPN. This
Lugyanti Sukrisman
doaj +1 more source
MDS/MPN With SF3B1 Mutation and Thrombocytosis but Without Ring Sideroblasts
American Journal of Hematology, EarlyView.
Biswadip Hazarika, Barbara J. Bain
wiley +1 more source